Da Diovan elimineres biliært fandt CHMP også, at der skulle fastsættes en kontraindikation for patienter med alvorlige leversygdomme, og at det "ikke bør gives til patienter med alvorlig leverinsufficiens, cirrhose eller biliær obstruktion".
The CHMP also considered that in view of the fact that Diovan is eliminated via the biliary route, it should be contraindicated in patients with severe liver diseases and “ should not be administered in patients with severe hepatic impairment, cirrhosis or biliary obstruction.